Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 26;10:1003976. doi: 10.3389/fpubh.2022.1003976

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Li, Liu, Li, Wang, Feng, Cai, Wu, Zhao, Du, Zhang, Wang, Zhang and Qu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

PSM-adjusted OS and BCSS of BMBC patients with neoadjuvant chemotherapy plus surgical treatment and chemotherapy alone (stratified by molecular subtype). Kaplan–Meier (K–M) survival analysis: (A) OS of BMBC patients with HR+/HER2- subtype; (B) OS of BMBC patients with HR+/HER2+ subtype; (C) OS of BMBC patients with HR–/HER2+ subtype; (D) OS of BMBC patients with HR–/HER2– subtype; (E) BCSS of BMBC patients with HR+/HER2– subtype; (F) BCSS of BMBC patients with HR+/HER2+ subtype; (G) BCSS of BMBC patients with HR–/HER2+ subtype; (H) BCSS of BMBC patients with HR-/HER2- subtype. OS, overall survival; BCSS, breast cancer-specific survival; BMBC, bone metastatic breast cancer; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; PSM, propensity score matching.